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A randomized trial of cyclosporine in patients with steroid- States that leads to end-stage renal disease in both adults
resistant focal segmental glomerulosclerosis. and children. Its incidence rate in Caucasians is three
Background. A clinical trial of cyclosporine in patients with times more common, and in African Americans, it is sixsteroid-resistant focal segmental glomerulosclerosis (FSGS)
times more common than the second leading cause [1, 2].was conducted. Despite the fact that it is the most common
Although its pathology, natural history, and response toprimary glomerulonephritis to progress to renal failure, treat-
ment trials have been very limited. corticosteroids treatment in both children and adults
Methods. We conducted a randomized controlled trial in 49 have been more clearly defined since its initial descrip-
cases of steroid-resistant FSGS comparing 26 weeks of cyclospo- tion over 40 years ago [3–16], the number of randomized
rine treatment plus low-dose prednisone to placebo plus pred-
controlled drug trials in this disorder has been very lim-nisone. All patients were followed for an average of 200 weeks,
ited [17–19], and such a study in adults with pathologyand the short- and long-term effects on renal function were
restricted to FSGS has never been reported.assessed.
Results. Seventy percent of the treatment group versus 4% Cyclosporine is a well known and effective immuno-
of the placebo group (P , 0.001) had a partial or complete suppressive agent that has become a cornerstone of im-
remission of their proteinuria by 26 weeks. Relapse occurred munotherapy in solid organ transplantation since thein 40% of the remitters by 52 weeks and 60% by week 78, but
first trial was published over a decade ago [20]. This drugthe remainder stayed in remission to the end of the observation
has been used in the treatment for FSGS for over 10period. Renal function was better preserved in the cyclosporine
group. There was a decrease of 50% in baseline creatinine years, but the studies have been open label and nonran-
clearance in 25% of the treated group compared with 52% of domized or have been a mixture of pathology and/or
controls (P , 0.05). This was a reduction in risk of 70% (95% age groups [17–19, 21–31]. Although a benefit in both
CI, 9 to 93) independent of other baseline demographic and children and adults has been reported, enthusiasm forlaboratory variables.
its use has been tempered by both a high relapse rateConclusions. These results suggest that cyclosporine is an
and a concern about the known nephrotoxicity of theeffective therapeutic agent in the treatment of steroid-resistant
cases of FSGS. Although a high relapse rate does occur, a long- agent [30, 32, 33]. We report the first long-term prospec-
term decrease in proteinuria and preservation of filtration func- tive controlled trial using cyclosporine in adults with
tion were observed in a significant proportion of treated patients. biopsy-proven FSGS resistant to corticosteroid therapy.
METHODSFocal segmental glomerulosclerosis (FSGS) is now the
This prospective single-blind, randomized trial wasmost common primary glomerulonephritis in the United
performed in 12 clinical centers in North America. The
study protocol was reviewed and approved by each cen-
Key words: FSGS, cyclosporine, glomerulonephritis, immunosuppres- ter’s institutional review board, and a signed informed
sion, nephrotoxicity. consent was obtained from all patients prior to entry.
Received for publication March 15, 1999 Entry criteriaand in revised form June 29, 1999
Accepted for publication July 19, 1999 Age at entry was between 18 and 70 years. All patients
must have failed to achieve a remission of the proteinuria 1999 by the International Society of Nephrology
2220
Cattran et al: Cyclosporine in FSGS 2221
after a minimum of eight weeks of prednisone at $1 mg/ four-week intervals to zero by eight weeks. A seated
blood pressure of #130 mm Hg systolic and #85 mm Hgkg/day. The following qualifiers had to be fulfilled for
the full six months prior to randomization: (a) protein- diastolic was targeted as the upper limit of accepted
values during the study. Any patient who was on eitheruria $3.5 g/day or $50 mg/kg, (b) creatinine clearance
(CCr) $42 ml/min/1.73 m2, (c) blood pressure #135/90 an angiotensin-converting enzyme inhibitor (ACEi) or
an angiotensin II receptor antagonist from the start ofmm Hg, and (d) dietary protein intake #0.8 g/kg. All
patients were required to have a renal biopsy performed the pretrial six-month run-in period could remain on it
during the study, but the introduction of these classeswithin three years of trial entry, and the local pathology
review had to confirm the presence of at least one classic of drug was forbidden during the test medication period.
All other antihypertensive agents were allowed. PatientsFSGS lesion [3]. Patients with features of collapsing
glomerulopathy were excluded. The renal tissue was sub- were placed on a diet consisting of #0.8 g/kg of protein
plus, in most cases, a no added salt, low cholesterol intakesequently reviewed by a nephropathologist masked to
patient assignment who scored each biopsy 0 to 31 at the start of the observation period.
Each patient had a minimum of three protocol visits(none, mild, moderate, or severe) with regards to three
areas: the percentage of glomeruli with either segmental prior to randomization with two mandated within the
six-week period prior to the start of the test medication.or global sclerosis, interstitial fibrosis, and vascular dam-
age. Immunofluorescence and electron microscopy were At randomization, a full history and physical evaluation,
as well as laboratory tests, including serum creatinine,also reviewed to rule out other types of renal disease
known to be associated with segmental sclerotic lesions. 24-hour urinary excretion estimates of protein, creati-
nine and urea, a lipid profile including cholesterol andExclusion criteria included women unwilling to take
effective birth control measures, comorbid conditions triglyceride estimations, and screening tests to rule out
potential secondary causes of FSGS, were performed.with expected survival of less than two years, any serious
systemic infection and associated disorders requiring An inclusion/exclusion checklist was maintained cen-
trally and reviewed prior to group assignment. The renaldaily nonsteroidal anti-inflammatory medications. Pa-
tients with diabetes mellitus and conditions known to function tests were repeated on the day of randomiza-
tion, and follow-up visits were scheduled for one, two,be associated with FSGS lesions such as obesity and
unilateral renal agenesis were also excluded. No immu- four, six, and eight weeks and then at four-week intervals
until the end of the test medication period, and then atnosuppressive agents, plasma exchange therapy, or anti-
lymphocyte products were allowed in the six months eight-week intervals until a study end point was reached
or data closure (January 1, 1998). If specific immunosup-prior to the start of the test medication period.
pressive drugs or corticosteroids were started at any time
Randomization and treatment after the test medication period, the patients were cen-
sored at that point. At each visit, the patient’s clinicalRandomization was performed by the clinical coordi-
nating center from a table of random numbers and was status and vital signs were recorded, and electrolytes,
hematology, renal, and liver functions were monitored.stratified by center in blocks of two to ensure a balance
between groups. The patients were masked in regards As well, cyclosporine trough values were obtained at
these intervals during the first 26 weeks. Compliance wasto active versus placebo assignment, but the physicians
were not for safety reasons and because the end points determined by the consistency of the cyclosporine level
and by a monthly check of the total volume consumedwere objective and measured centrally by a lab masked
to patient designation. Cyclosporine in a drink solution of the test medication. Serum creatinine and 24-hour
urinary excretion of creatinine, protein, and urea at each(100 mg/ml) and an identical placebo made from the same
carrier were provided by Novartis Canada Ltd. (Whitby, visit were measured by a central laboratory using stan-
dard methods.Ontario, Canada). Treatment was started at a dose of
3.5 mg/kg/day in the active group and 0.035 ml/kg in the
Outcome measuresplacebo group. The daily quantity was divided and given
in two equal doses at 12-hour intervals. Adjustments in The primary outcome was the number of complete or
partial remissions in proteinuria by week 26. This wasdose were made in the cyclosporine group to achieve a
whole blood 12-hour trough level measured by mono- also assessed at 52, 78, and 104 weeks, and at the last
follow-up. Complete remission was defined as #0.3 g/dayclonal assay, between 125 and 225 mg/liter. A comparable
number of adjustments were made in the placebo volume proteinuria plus stable renal function. A partial remis-
sion was defined as a 50% reduction of initial proteinuriato ensure that masking was maintained. The test medica-
tions were continued for 26 weeks and then tapered to and #3.5 g/day with stable renal function. Stable function
was defined as a CCr estimate that was within 15% ofzero over four weeks. All study patients also received
prednisone at 0.15 mg/kg/day (maximum daily dose of the initial value. Secondary analyses included time to a
50% reduction in baseline CCr and time to doubling of15 mg). This was reduced after 26 weeks by thirds at
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Table 2. Central review of renal pathologyTable 1. Baseline demographic and laboratory data of the 49
randomized patients
Characteristics Placebo Cyclosporine
Placebo Cyclosporine
GlomeruliCharacteristics N 5 23 N 5 26
% Segmental sclerosis 20 (15–50)a 27 (4–60)
% Global sclerosis 16 (0–20) 13 (5–30)Age (range) 40 614 (20–73) 38 610 (19–59)
Gender % males 74 65 Interstitial disease
% #11 78 65Blood pressure mm Hg
Systolic 134616 136613 % $21 22 35
Vascular damageDiastolic 8568 8767
Racial group N (%) % #11 78 81
% $21 22 19Caucasians 20 (87) 23 (88)
African Americans 3 (13) 1 (4) a Numbers in parentheses signify range
Other — 2 (8)
Serum albumin g/dl 3.060.9 3.160.9
Creatinine mg/dla 1.460.6 1.360.4
Creatinine clearance
ml/min/1.73m2 86631 86627 vation period. Values in the tables are means 6 sd unless
Proteinuria g/day 8.764.7 6.963.3
otherwise stated. The analyses were performed with theUrine urea g/day 9.863.9 9.763.4
Statistical Analysis System Software [34]. The relativeData that are 6 values are standard deviations.
a To convert to mmol/l, multiply by 88.4 benefit of treatment was also assessed by calculating the
number of patients who would need to be treated to
prevent one outcome event defined by a 50% reduction
in baseline CCr [35].
baseline creatinine. Study end points included end-stage
renal disease defined as a CCr ,12 ml/min, start of dial-
RESULTSysis, or transplantation or study closure. Early stop points
of the test medication included a confirmed $30% rise Sixty patients were screened and deemed eligible by
in baseline serum creatinine. Confirmed meant that the the local principal investigator, and signed a consent
creatinine was not improved by two 25% reductions in form. Review subsequently excluded 11 patients prior
the dose of the test medication, spaced out over a four- to randomization because of a failure to confirm the
week period. Other premature stop points included dou- histological diagnosis (N 5 4), central measurement of
bling of baseline liver enzymes and intolerable side ef- proteinuria , 3.5 g/day (N 5 2), CCr , 42 ml/min (N 5 4),
fects. As well, the test medication was discontinued early and a positive antinuclear factor (N 5 1).
if complete remission of proteinuria was achieved and The total prednisone dose given prior to the six-month
persisted for a minimum of one month. run-in period was not different in the two groups. In the
placebo patients, the mean was 100 mg/kg (range 80 to
Data analysis 140), and in the cyclosporine patients, it was 120 mg/kg
A prospective construction of sample size based on (range 70 to 150). The mean duration of treatment was
an analysis of two independent proportions using an a also similar at 14 weeks in the placebo patients (range
of 0.05 and a b of 0.2 and a difference in remission rates 10 to 48) and 13 weeks in the cyclosporine patients (range
in proteinuria at 26 weeks of 30% plus a drop out rate 10 to 60). In addition, 11 patients (5 placebo and 6 cyclo-
of 10%, indicated that 25 patients per arm were needed. sporine) had received a course of a cytotoxic agent (9
The subsequent results were analyzed by chi square for cyclophosphamide and 2 azathioprine) in a dose range of
proportions and, if appropriate, the nonparametric Mann– 1 to 3 mg/kg for a mean of two months (range 1 to 16).
Whitney rank sum test. The length of time to event There were no significant differences in any of the
analysis utilized Kaplan–Meier product-limit life-table demographic or laboratory features at baseline (Table 1).
survival estimates compared by the log-rank test. All The racial group was predominantly Caucasian, and the
tests were two sided and analyzed on the basis of all male to female ratio was approximately 2:1. The urine
patients maintained in their original assigned group. Pro- urea, a reflection of dietary protein intake, was equal in
portional hazards regression was used to determine pos- both groups at entry. The central pathology review of
sible interactions between treatment groups and baseline the renal biopsy tissue is detailed in Table 2. All patients
covariates, including age, gender, proteinuria, albumin, were documented to have at least one focal segmental
systolic and diastolic blood pressure, and grade of inter- sclerotic lesion. The percentage of glomeruli with seg-
stitial fibrosis on biopsy, as well as to estimate the reduc- mental lesions was variable from patient to patient, but
tion in the number of events within groups. Differences the mean was not different between groups. The overall
in renal functions over time were compared by t-test of interstitial fibrosis score and degree of vascular damage
the slopes of CCr and reciprocal of creatinine over the and their ranges were also very similar in both populations.
The effects of the test medication on the proteinuria26 weeks of the test medications and over the total obser-
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Fig. 1. Remission in proteinuria in the cyclosporine treated ( , partial;
j, complete) compared with the placebo treated (h, partial) at different
time points of the study. At week 26, P , 0.001, and at 104 weeks
P , 0.05.
Fig. 2. Percentage of cyclosporine patients (d) compared with placebo
(s) who had a 50% loss in renal function as measured by CCr over thein the two groups over time is illustrated in Figure 1. observation period. The number of patients being followed at different
time points is listed in the table under the figure (P , 0.05).Remission of proteinuria occurred in 69% of the cyclo-
sporine group (12% complete and 57% partial) com-
pared with a 4% partial remission rate in the placebo
group by the end of the 26 weeks of active treatment
min/year in the two groups at the end of six months of(P , 0.001). The time to complete remission ranged
active treatment was the same, but over the study period,from 1 to 25 weeks and to partial remission from 1 to
the mean was 25.5 ml/min 6 18 in the cyclosporine15 weeks with a mean of seven weeks. Two of three
group compared with 223 ml/min 6 39 in the placebo(66%) in complete remission and 6 of 15 (40%) in partial
group (P , 0.05). Fourteen patients reached end-stageremission in the cyclosporine group relapsed by week 52.
renal disease by study closure (10 placebo and 4A further three relapses and one new partial remission
cyclosporine). The renal survival rate was 72% in theoccurred by week 78 in this group. One further partial
cyclosporine group compared with 49% in the placeboremission occurred in the placebo group at week 65.
group at four years (P 5 0.1). Seven patients were fol-The percentage in remission then remained essentially
lowed less than 78 weeks because of the onset of end-unchanged at week 78 and 104. There was no statistical
stage renal disease in six and because of relocation out-relationship in those who relapsed versus those who re-
side of North America in one. The latter patient was inmained long-term remitters between either the nadir
the cyclosporine group, and her proteinuria and creati-or percentage reduction achieved from their baseline
nine had remained unchanged during both the treatmentproteinuria.
period and in follow-up to week 36.Renal failure by log-rank test using a 50% reduction
The mean dose of cyclosporine over the treatmentin baseline CCr as an end point was seen in 25% of
period was 4.2 6 2.1 mg/kg. All patients completed sixthe cyclosporine-treated patients compared with 52% of
months of the test medication, except one on cyclosporine,placebo patients by four years (P , 0.05; Fig. 2). Partial
who had a complete remission by week 8 and stoppedor complete remission of proteinuria whether they subse-
the drug at week 12 and one who stopped cyclosporinequently relapsed was also significantly correlated with
after 12 weeks because of persistent nausea and vom-long-term preservation of renal function (P , 0.03). This
iting. An increase in baseline creatinine of 30% incurredwas not absolute because four partial remission patients
in six patients, two on placebo and four on cyclosporine.(treatment 5 3, placebo 5 1) went on to reach a CCr end
After a dose adjustment, none in the placebo group butpoint. The number of patients needed to treat to prevent
all four in the cyclosporine group had an improvementone occurrence of this end point was five. The associated
in their creatinine value and remained on the test medica-reduction in risk of progression was 70% (95% CI, 9 to
tion to week 26. Compliance, as judged by a monthly93) unaltered by any of the initial covariates examined,
measurement of the volume of the test medications used,including age, gender, systolic and diastolic blood pres-
was $90% in all patients.sure, severity of baseline proteinuria, and degree of tubu-
lar interstitial disease on biopsy. The slope of CCr in ml/ At randomization, 26% (N 5 13) of patients were
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DISCUSSION
Focal segmental glomerulosclerosis was initially de-
scribed 40 years ago. It is currently the most common
primary glomerular disease to progress, and its incidence
rate is increasing [1, 2, 12]. Although never formally
tested, corticosteroid treatment is associated with a com-
plete remission rate of between 20 and 40% [5–8]. This
type of response has also been noted to be the best single
guide to an excellent long-term prognosis. In contrast,
patients who do not respond have a higher likelihood
of progressing to renal failure. This was our rationale
for the entry criteria of failure to respond to a minimum
of eight weeks of daily prednisone. The actual mean
prednisone dose and duration were significantly greater
Fig. 3. Mean sitting systolic and diastolic pressures at the end of each than this minimum, and in addition, 22% had failed a
time period by groups. Symbols are: (j) cyclosporine; (h) placebo. course of cytotoxic therapy. The total dose and durationThe bars represent standard deviations.
of prednisone were equal to or above the amount given
to induce remission in our earlier studies [5, 36]. In spite
of this selection bias, our results demonstrated a signifi-
normotensive (5 placebo and 8 cyclosporine), and 74% cant effect of treatment with a reduction in proteinuria
(N 5 36) were hypertensive. In the latter group, 21 were in 69% of the cyclosporine group, either partial (57%)
on ACEi (10 placebo and 11 cyclosporine), and 15 were or complete remission (12%), compared with a very low
on other antihypertensive drugs (8 placebo and 7 cyclo- partial remission (4%) in the placebo group. Although
the relapse rate was substantial with approximately 60%sporine). No significant differences in supine, sitting, or
relapsing within the first-year post-test medication, themean arterial blood pressure were noted during either
remainder stayed in remission until the last follow-up.the active medication period or during the postdrug pe-
As well, the remission group, even if they subsequentlyriod (Fig. 3). During the post-test medication period,
relapsed, generally had a better long-term preservationhypertension worsened in both groups, and additional
of filtration function, although as discussed, there wereantihypertensive drugs were required. By the time the
exceptions. Overall, however, a loss of 50% of renal func-patient reached either a stop point or the last observation
tion as measured by the halving of baseline CCr was seenpoint, 88% (23 patients) in the cyclosporine group and
in only one quarter of our cyclosporine patients, but over87% (20 patients) in the placebo group were on at least
half of our placebo group. In our multivariate analysis,one antihypertensive agent. At that point, an ACEi was
the risk reduction of progression in the cyclosporineemployed either alone or in combination with other anti-
group was 70% (95% CI, 9 to 93) compared with placebo.hypertensive agents in 65% of the cyclosporine group
A report from the only randomized controlled trial inand 85% of the placebo group (P 5 NS).
children with FSGS demonstrated a mean reduction in
proteinuria of 70 6 20% compared with 11 6 29% in theAdverse effects
placebo group after six months of treatment [18]. The
Although the mean blood pressure in the cyclosporine
quantitative reduction was from 152 mg/kg to 37 mg/kg
patients was maintained at the same level as the placebo body wt in the treated versus no change in the placebo
group during the treatment period, a new agent or an group. In the only other controlled trial that included both
increase in their antihypertensive drug dosage was re- adults and children but a mixture of minimal change and
quired in eight of the cyclosporine patients and only two FSGS pathology, the authors found a remission rate of
of the placebo group. The other significant adverse effect 60% with cyclosporine compared with 15% with conserva-
was in one patient who had gastrointestinal symptoms tive treatment after 12 months [17]. They also found that
on cyclosporine and had to stop the medication after 12 long-term remission was preserved in approximately half
weeks of treatment. All 49 patients were maintained on of their responders assessed at 12 months post-treatment.
their prescribed prednisone dose for 26 weeks without There was no follow-up with regards to renal function
any adverse effect. in the study in children [18]. In the adult trial, although
Dietary compliance over the study period was good the postmedication period was limited in both numbers
with only 16% of the patients (4 placebo and 3 cyclospo- of patients and the observation time, the decline in CCr,
rine) consistently more than 20% above the recom- albeit not statistically significant, was slower, both during
mended dietary protein intake, as assessed by monthly the treatment and in the 12 months of follow-up in the
cyclosporine group [17].24-hour urinary urea estimates.
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